Change search
ReferencesLink to record
Permanent link

Direct link
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Medicine and Health Sciences.
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Show others and affiliations
2016 (English)In: Scientific Reports, ISSN 2045-2322, E-ISSN 2045-2322, Vol. 6, 1-14 p., 26979Article in journal (Refereed) PublishedText
Abstract [en]

Inhibition of deubiquitinase (DUB) activity is a promising strategy for cancer therapy. VLX1570 is an inhibitor of proteasome DUB activity currently in clinical trials for relapsed multiple myeloma. Here we show that VLX1570 binds to and inhibits the activity of ubiquitin-specific protease-14 (USP14) in vitro, with comparatively weaker inhibitory activity towards UCHL5 (ubiquitin-C-terminal hydrolase-5). Exposure of multiple myeloma cells to VLX1570 resulted in thermostabilization of USP14 at therapeutically relevant concentrations. Transient knockdown of USP14 or UCHL5 expression by electroporation of siRNA reduced the viability of multiple myeloma cells. Treatment of multiple myeloma cells with VLX1570 induced the accumulation of proteasome-bound high molecular weight polyubiquitin conjugates and an apoptotic response. Sensitivity to VLX1570 was moderately affected by altered drug uptake, but was unaffected by overexpression of BCL2-family proteins or inhibitors of caspase activity. Finally, treatment with VLX1570 was found to lead to extended survival in xenograft models of multiple myeloma. Our findings demonstrate promising antiproliferative activity of VLX1570 in multiple myeloma, primarily associated with inhibition of USP14 activity.

Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP , 2016. Vol. 6, 1-14 p., 26979
National Category
Cell and Molecular Biology
URN: urn:nbn:se:liu:diva-129664DOI: 10.1038/srep26979ISI: 000377072700001PubMedID: 27264969OAI: diva2:943227

Funding Agencies|Cancerfonden; Radiumhemmets forskningsfonder; Vetenskapsradet; Barncancerfonden

Available from: 2016-06-27 Created: 2016-06-23 Last updated: 2016-07-26

Open Access in DiVA

fulltext(2851 kB)7 downloads
File information
File name FULLTEXT01.pdfFile size 2851 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wang, XinSelvaraju, KarthikLinder, StigD´arcy, Padraig
By organisation
Division of Drug ResearchFaculty of Medicine and Health SciencesDepartment of Medical and Health Sciences
In the same journal
Scientific Reports
Cell and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 7 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 33 hits
ReferencesLink to record
Permanent link

Direct link